Lupin and Celon Pharma S.A. (Celon) announced that they have entered into a definitive agreement under which the companies will jointly develop fluticasone / salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus. Lupin will be responsible for commercialization of the product. Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico and other key markets.
Powered by Capital Market - Live News
